<DOC>
	<DOC>NCT01646489</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and affect on blood levels of miravirsen and telaprevir when administered together.</brief_summary>
	<brief_title>Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Healthy volunteers Weight â‰¤ 85 kg Females of nonchildbearing potential (postmenopausal or surgically sterile) or males who are surgically sterile or using an acceptable form of birth control Current, clinically significant illness or medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Antisense</keyword>
	<keyword>miR-122 antagonist</keyword>
	<keyword>Safety in healthy volunteers</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>